Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
131.07
+0.59 (0.45%)
At close: Jul 24, 2026, 4:00 PM EDT
130.99
-0.08 (-0.06%)
After-hours: Jul 24, 2026, 7:58 PM EDT
Merck & Co. Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 65,768 | 65,011 | 64,168 | 60,115 | 59,283 | 48,704 |
Revenue Growth | 2.89% | 1.31% | 6.74% | 1.40% | 21.72% | 17.31% |
Gross Profit Gross Profit Growth | 48,610 | 48,629 | 48,975 | 43,989 | 41,872 | 35,078 |
Operating Income Operating Income Growth | 11,955 | 21,218 | 19,912 | 2,355 | 17,945 | 12,538 |
Net Income Net Income Growth | 8,935 | 18,254 | 17,117 | 365 | 14,519 | 13,049 |
Earnings Per Share EPS Growth | 3.55 | 7.28 | 6.74 | 0.14 | 5.71 | 4.86 |
EPS Growth | -48.33% | 8.01% | 4714.29% | -97.55% | 17.49% | 74.82% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Keytruda/Keytruda Qlex Keytruda/Keytruda Qlex Growth | 32,509 | 31,681 | 29,482 | 25,011 | 20,937 | 17,186 |
Gardasil/Gardasil 9 Gardasil/Gardasil 9 Growth | 4,975 | 5,233 | 8,583 | 8,886 | 6,897 | 5,673 |
Januvia/Janumet Januvia/Janumet Growth | 2,322 | 2,544 | 2,268 | 3,366 | 4,513 | 5,288 |
ProQuad/M-M-R II/Varivax ProQuad/M-M-R II/Varivax Growth | 2,450 | 2,451 | 2,485 | 2,368 | 2,241 | 2,135 |
Bridion Bridion Growth | 1,871 | 1,841 | 1,764 | 1,842 | 1,685 | 1,532 |
Lynparza - Alliance Lynparza - Alliance Growth | 1,479 | 1,450 | 1,311 | 1,199 | 1,116 | 989 |
Winrevair Winrevair Growth | 1,688 | 1,443 | 419 | - | - | - |
Lenvima - Alliance Lenvima - Alliance Growth | 1,051 | 1,053 | 1,010 | 960 | 876 | 704 |
Animal Health Animal Health Growth | 6,557 | 6,354 | 5,877 | 5,625 | 5,550 | 5,568 |
Other Product Other Product Growth | 358 | 515 | 891 | 907 | 1,728 | 382 |
Revenue (Total) Revenue (Total) Growth | 65,768 | 65,011 | 64,168 | 60,115 | 59,283 | 48,704 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 5,702 | 14,565 | 13,689 | 7,093 | 13,192 | 8,096 |
Total Debt Total Debt Growth | 49,117 | 49,339 | 37,111 | 35,055 | 30,691 | 33,102 |
Net Cash (Debt) Net Cash Growth | -43,415 | -34,774 | -23,422 | -27,962 | -17,499 | -25,006 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -17.42 | -13.87 | -9.22 | -10.98 | -6.88 | -9.85 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 17,890 | 16,472 | 21,468 | 13,006 | 19,095 | 14,109 |
Capital Expenditures CapEx Growth | -3,775 | -4,112 | -3,372 | -3,863 | -4,388 | -4,448 |
Free Cash Flow Free Cash Flow Growth | 14,115 | 12,360 | 18,096 | 9,143 | 14,707 | 9,661 |
Free Cash Flow Growth | -17.16% | -31.70% | 97.92% | -37.83% | 52.23% | 65.88% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 73.91% | 74.80% | 76.32% | 73.17% | 70.63% | 72.02% |
Operating Margin | 18.18% | 32.64% | 31.03% | 3.92% | 30.27% | 25.74% |
Pretax Margin | 17.68% | 32.41% | 31.07% | 3.14% | 27.74% | 28.50% |
Profit Margin | 13.58% | 28.09% | 26.70% | 0.63% | 24.50% | 25.37% |
FCF Margin | 21.46% | 19.01% | 28.20% | 15.21% | 24.81% | 19.84% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 26, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 3.400 | 3.240 | 3.080 | 2.920 | 2.760 | 2.600 |
Dividend Per Share Growth | 5.00% | 5.20% | 5.48% | 5.80% | 6.15% | 6.56% |
Dividend Yield | 2.59% | 3.10% | 3.11% | 2.69% | 2.50% | 3.41% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 26, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 36.65 | 14.46 | 14.76 | 778.71 | 19.43 | 15.77 |
Forward PE | 21.20 | 12.18 | 11.05 | 17.47 | 15.45 | 10.97 |
P/FCF Ratio | 22.93 | 21.07 | 13.90 | 30.19 | 19.15 | 20.05 |
PS Ratio | 4.92 | 4.01 | 3.92 | 4.59 | 4.75 | 3.98 |